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Accepted 11 August 2013The idiopathic pulmonary arterial hypertension is a complex disease that mainly affects pulmonary arte-
rial circulation. This undergoes a remodeling with subsequent reduction of ﬂow in the small pulmonary
arteries. Because of this damage an increased vascular resistance gradually develops, and over time it car-
ries out in heart failure. The inﬂammatory process is a key element in this condition, mediated by various
cytokines. The inﬂammatory signal induces activation of NF-jB, and prompts TGF-b-related signaling
pathway. Clinical evolution leads to progressive debilitation, greatly affecting the patient quality of life.
The actual therapeutic approaches, are few and expensive, and include systemic drugs such as prosta-
noids, phosphodiesterase inhibitors and antagonists of endothelin-1 (ERBs). Some researchers have long
investigated the anti-inﬂammatory effects of curcumin. It shows a role for inactivation of
NF-jB-mediated inﬂammation. On the basis of these ﬁndings we propose a potential role of curcumin
and its pharmacologically ﬁt derivatives for treatment of idiopathic pulmonary arterial hypertension.
 2013 Elsevier Ltd. All rights reserved.Introduction
The pulmonary arterial hypertension was considered for a long
time a rare disease. In 2006 from a French registry its prevalence
has been estimated in about 15 per million. The idiopathic pul-
monary arterial hypertension (IPAH) is more prevalent in women
and is the most common type of pulmonary arterial hypertension.
An arterial remodeling, affecting the arteries of the pulmonary
arterial circulation, underlies this complex disorder. It leads to a
reduction of ﬂow in the small arteries, which develops increased
vascular resistance, and over time it ends in heart failure [1]. This
condition is the result of a sum of events, as it is the case for dis-
eases such as atherosclerosis or systemic arterial hypertension.
Among these events some researchers identiﬁed BMPR2 gene
germline mutation, which codes for a protein belonging to TGFb
family. BMPR2 modulates the vascular cells growth via activation
of SMAD and LIM kinases. Therefore the mutation leads to an alter-
ation of signal transduction within the vascular smooth muscle
cells with alteration of the balance between cell proliferation and
apoptosis [2–4]. From an histo-pathological point of view, trigger-ing events are intimal hyperplasia, medial hypertrophy, adventitial
proliferation with in situ thrombosis, various degrees of inﬂamma-
tion and plexiform arteriopathy. Thus, the inﬂammatory process is
clearly a key element in the disease, as a matter of fact the B and T
lymphocytes, dendritic cells and macrophages involved, are all
called due to an increase in serum levels of cytokines IL-1b, IL-6,
IL-8 or TNFa. Chemokines (CCL-2/MCP-1, CCL-5/RANTES) also con-
tribute to it [2,3,5]. So it is explained why the pulmonary arterial
hypertension is often associated with ‘‘inﬂammatory’’ conditions
as polyneuropathy syndrome, systemic lupus erythematosus,
scleroderma, Hashimoto’s thyroiditis [1,6]. Growth factors contrib-
ute to the inﬂammatory process, together with cytokines, affecting
the remodeling that develops during the course of this disease.
They are PDGF (platelet-derived growth factor) that is expressed
in plexiform lesions together with the VEGF receptor 2 (VEGFR2),
EGF (epidermal growth factor), VEGF (vascular endothelial growth
factor), FGF2 (ﬁbroblast growth factor 2). Altered levels of bFGF
(basic) were detected in plasma and urine of patients with pul-
monary arterial hypertension. The inﬂammatory process involves
various ways that have as protagonists several transcription fac-
tors. It is important among these, the signaling activity of NF-jB
(nuclear factor j B), which is activated by several cytokines and
extracellular inﬂammatory triggers. The other major route, as
already seen, is the signaling pathway that involves the factors
belonging to the TGFb-signaling family [2,3]. The IPAH most com-
mon symptom is dyspnea on exertion. It indicates a progressive
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carbon monoxide and mixed venous oxygen saturation, leading to
hypoxemia and increased work of breathing. Other symptoms are
fatigue, lack of energy, angina, syncope, palpitations and peripheral
edema. Edema results from right ventricular failure and tricuspid
regurgitation. The physical examination shows accentuated pul-
monary component of S2, pansystolic murmur of tricuspid regurgi-
tation, jugular vein distension, hepatomegaly and ascites [5,8].Therapeutic approaches
They can be distinguished in a basal treatment and a speciﬁc
therapy. The ﬁrst one includes diuretics, mainly loop diuretics
and spironolactones, for right heart failure treatment and other
drugs for left heart failure such as angiotensin converting enzyme
inhibitors or angiotensin II receptor blockers or digoxin, chronic
oxygen and anticoagulants. On the other hand, there is the speciﬁc
medical therapy for idiopathic pulmonary arterial hypertension.
For a long time only calcium channel blockers were used, but it
was clariﬁed that only a little percent of patients responds to them.
So the current speciﬁc therapy took over. There are mainly three
types of drug, by acting on different routes, alone or in association.
Prostanoids, prostacyclin analogs, restore the imbalance between
thromboxane A2, a vasoconstrictor molecule, and prostacyclin, a
vasodilator molecule. This imbalance in favor of thromboxane A2
produces vasoconstriction to which thrombosis and platelet acti-
vation contribute. Phosphodiesterase inhibitors inhibiting PDE5
(Phosphodiesterase 5) prolong the time of permanence within
the cell of cGMP. This molecule belongs to the signaling pathway
starting from NO, thus producing a vasodilator effect for relaxation
of vascular smooth muscle cells. Another class of drugs in use is
represented by antagonists of endothelin-1 (ERBs). The latter is a
potent endogenous vasoconstrictor molecule, which is mitogen
on smooth muscle cells and therefore it also contributes to pul-
monary vascular hypertrophy [7,8]. The limit of the actual treat-
ments is that they are few, expensive and even more in a
combination therapy, and they have various side effects. The most
common are pain, headache, nausea, diarrhea and in some cases li-
ver toxicity.Curcumin as a possible therapeutic agent from diet
Turmeric (prepared from the root of the Curcuma longa) belongs
to the ginger family. It is more commonly available as a dried pow-
der, curry powder. Curry is a spice used for decades in traditional
Indian medicine for the treatment of various diseases such as
arthritis, ulcers, wounds, fever, trauma, as well as skin diseases,
for example psoriasis. Main active constituent of turmeric is curcu-
min, whose active constituent is diferuloylmethane, a hydrophobic
polyphenol, which gives the characteristic yellow-orange color to
curry [9,10]. Curcumin, demethoxycurcumin, bisdemethoxycurcu-
min and the more recent cyclocurcumin are the major components
(called curcuminoids) isolated from turmeric over the years. Over
the past 60 years studies have proven antioxidant, antibacterial,
antifungal, antiviral, anti-inﬂammatory, anti-proliferative, pro-
apoptotic and anti-atherosclerotic properties. These components
exert beneﬁcial effects to various diseases including cardiovascular
disease and pulmonary ﬁbrosis. The molecular targets are numer-
ous, the curcumin can bind them directly or modulate their activ-
ities or indirectly regulate the function. It has been seen that more
than 30 proteins interact directly with curcumin, including DNA
polymerase, protein kinase C, lipoxygenase. Growth factors, tran-
scription factors, kinases, inﬂammatory cytokines, adhesion mole-
cules, apoptosis-related proteins are its molecular targets. As
regards the transcription factors curcumin potently inhibits theactivation of NF-jB (nuclear factor j B), STAT proteins, HIF-1 (hy-
poxia-inducible factor-1), while on the other hand activates PPAR-
c (peroxisome proliferator activated receptor-c). The nuclear fac-
tors NF-jB, STAT-3, HIF-1 are involved in cell proliferation, cell sur-
vival, invasion, angiogenesis and inﬂammation [9]. It has been
shown that curcumin reversibly inhibits STAT3 activation in some
cells and by this mechanism it suppresses IL-6-induced cell prolif-
eration [11]. In inﬂammatory diseases there is a dysregulation of
NF-jB. Normally in unstimulated cells, NF-jB is constitutively
localized in the cytosol as a heterodimer bound to an inhibitory
protein called IjB, various pathogenic stimuli including cytokines,
ischemia/reperfusion can activate NF-jB through various path-
ways. Under activation NF-jB is translocated to the nucleus, where
it induces the expression of several target genes, that play a role in
inducing cell proliferation, invasion, inﬂammation. Curcumin pre-
vents NF-jB activation induced by various agents through the inhi-
bition of translocation of p65 to the nucleus and suppressing IjBa
degradation in numerous cytotypes. Curcumin, by inhibiting NF-
jB activation, suppresses the expression of various cell survival
and proliferative genes, including IL6 and cyclooxygenase 2, it
inhibits proliferation and induces apoptosis. Curcumin modulates
the expression and activity of some growth factors, including TGFa
(transforming growth factor a), EGFR (epidermal growth factor
receptor), a member of the ErbB family receptors. In this case, cur-
cumin blocks the signaling pathway EGFR preventing tyrosine
phosphorylation and suppressing the EGFR gene expression, that
is mediated by activation of PPAR-c [9]. It may directly inhibit
angiogenesis and also downregulate expression of vascular endo-
thelial growth factor (VEGF), ﬁbroblast growth factor (FGF) and
EGF [12]. Interleukins are another group of inﬂammatory cytokines
that play a critical role in the regulation of inﬂammation response,
as well as signaling pathways such as NF-jB and the STATs [9].
Inhibition of pro-inﬂammatory cytokine production by regulation
of transcriptional factors, such as NF-jB, is a potential strategy
for controlling inﬂammatory responses [13,14]. Excessive synthe-
sis and production of pro-inﬂammatory cytokines, including TNF-
a, IL-1b and IL-6, play a major role in the development of local
and systemic inﬂammation, causing severe pathophysiological
derangement or organ failure [15]. Several studies have demon-
strated that curcumin was able to modulate the production of var-
ious inﬂammatory cytokines, thereby exhibiting potent anti-
inﬂammatory activity [16,17]. It reduces the expression of IL-1b,
IL-6 and IL-8 through suppression of NF-jB and MAPK pathways
[9,10]. TNF-a plays an important role in immune cells regulation
and the development of systemic inﬂammation. Dysregulation of
TNF-a production has been implicated in a variety of inﬂammatory
diseases. Curcumin has profound inhibitory effects on the produc-
tion of TNF-a and it also showed effects on modulation of TNF-a-
induced signaling [9]. It can down-regulate or suppress NF-jB acti-
vation induced by TNF-a. The mechanism appears to be via a re-
duced IkBa phosphorylation and degradation, suggesting that
curcumin acts at a step above IkB kinase (IKK) in the NF-jB activa-
tion pathway. Many of the observed biological effects of curcumin
involve processes that are NF-jB-dependent [10]. In endothelial
cells, treatment with curcumin suppressed TNF-induced NF-jB
activation and the expression of adhesion molecules, thereby
inhibiting the adhesion of monocytes to endothelial cells [18]. En-
zymes closely associated with inﬂammation like COX-2, inducible
nitric oxide synthase (iNOS), 5-LOX, and phospholipases A2
(PLA2) are modulated by curcumin. It can downregulate the
expression and the activity of COX-2 both in vitro and in vivo
[9]. Curcumin inhibits COX2 production and inhibits COX2 induc-
tion. The COX2 gene promoter contains two NF-jB binding sites
and show evidence that the effect of curcumin on COX2 is due to
inhibition of NF-jB binding. The level of impact of curcumin upon
the NF-jB pathway appears to be at or above IKK. A very important
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fects of chronic aspirin or non-steroidal anti-inﬂammatory drugs
ingestion [10]. Inhibition of NF-jB completely blocked TNF-a-in-
duced expression of ICAM-1, VCAM-1, and E-selectin, indicating
that the expression of CAMs is regulated in part by NF-jB. Curcu-
min potently inhibited TNF-a-induced expression of ICAM-1,
VCAM-1, and ELAM-1 partially through NF-jB inhibition. As re-
gards the pharmacokinetics, safety and efﬁcacy of curcumin, it is
remarkably well tolerated. Even at high doses, curcumin appears
nontoxic to humans. If curcumin is administered as a single daily
oral dose ranging from 500 to 8000 mg/day for 3 months, the treat-
ment is well tolerated [9]. Oral doses up to 12 g/day are well toler-
ated in human subjects [19], although dosing diet regimen above
8 g may be difﬁcult to achieve due to the bulky nature of this quan-
tity of compound [20]. Although curcumin is well tolerated and has
a wide variety of beneﬁcial activities and possesses good pharma-
cological properties, its bioavailability in vivo is poor. This may be
an important obstacle to its utility as a potential therapeutic agent
[9]. Drug delivery is a problem and the bioavailability of oral cur-
cumin is low due to a combination of rapid and efﬁcient ﬁrst pass
metabolism, poor gastrointestinal absorption, rapid systemic elim-
ination and poor aqueous solubility [10,21]. A clinical study
showed that serum levels of curcumin were undetectable or very
low after 2 g of pure curcumin powder was administered alone
to fasting volunteers [22]. Curcumin undergoes avid glucuronida-
tion and sulfation leading to the formation of curcumin glucuro-
nide and, less commonly, curcumin sulfates. It was suggested
that the low systematic bioavailability of curcumin may be due
to the hydrophobic nature of the molecule, poor absorption and
the metabolic biotransformation in intestine and liver [23]. These
conjugates are detectable in plasma at greater concentrations than
free curcumin with a peak at 4 h after oral dosing [24]. This may be
explained by the fact that curcumin constitutes about 5% of tur-
meric root; the remainder is made up of carbohydrates, proteins
and essential oils [10]. Several approaches have been tried to im-
prove the bioavailability of curcumin. These approaches include
the use of adjuvants such as piperine, the use of liposomal curcu-
min, curcumin nanoparticles, the use of curcumin phospholipid
complex, and the use of structural analogs of curcumin [9,10]. It
has been reported that heat treatment improves the water solubil-
ity of curcumin [10]. Piperine is an inhibitor of curcumin glucuron-
idation in the liver [21]. Shoba et al. reported that combined
treatment with curcumin and piperine (20 mg/kg) produced higher
serum concentration of curcumin from 0.25 to 1 h post-drug and
increased the bioavailability by 2000% [22]. So, the clinical use of
curcumin has been limited by its low solubility and poor oral bio-
availability. Delivery by inhalation for the treatment of pulmonary
disease likewise appears infeasible, because the organic solvents in
which it must be dissolved are toxic to the lung. To overcome these
drug-delivery obstacles, it has been developed a new formulation
of curcumin in which it is complexed with hydroxypropyl ether
derivatives of cyclodextrin (CDC). This formulation of curcumin is
stable, highly water-soluble, bioavailable, and easily produced.
This permits administration by either the intravenous or inhalation
routes at doses that have been shown to elicit anti-inﬂammatory
effects. CDC is rapidly cleared from the circulation after intrave-
nous administration. The oral bioavailability of curcumin is low be-
cause of metabolism in the intestine, which would presumably
affect oral CDC as well. These limitations make inhalation a viable
route of administration for CDC, particularly for the targeted treat-
ment of inﬂammatory lung disease [25]. In human trials, only a
minor side effect of curcumin, namely diarrhea [26], has been re-
ported. Curcumin is considered safe and well tolerated [10]. Even
though curcumin exhibits a wide variety of pharmacological activ-
ities and has been found to be quite safe in humans, there are some
reports concerning its toxicity. It has been reported that curcuminexhibit both antioxidant and pro-oxidant activities. It is possible
that these opposing activities of curcumin are regulated by its con-
centration, so the effect of curcumin may switch from antioxidant
to pro-oxidant. Nevertheless no long-term studies have been con-
ducted to show curcumin toxic or adverse effects so far. Such stud-
ies are necessary in human subjects to determine the safety of
curcumin in a long period of time [21].
The hypothesis
The problem of IPAH treatment is that available drugs are few,
expensive, even more in a combination therapy, and they have var-
ious side effects. We propose curcumin as possible therapeutic
solution for IPAH. It inhibits main pathways underlying this dis-
ease. Curcumin exhibits suppression on the NF-jB pathway deter-
mining, through this way, also a control on inﬂammatory cytokines
IL-1b, IL-6 and IL-8. Through the same way it controls COX2 pro-
duction and COX2 induction. Curcumin inhibits TNF-a, another
element that takes part to the inﬂammatory process. It modulates
inducible nitric oxide synthase (iNOS), 5-LOX, and phospholipases
A2 (PLA2). So, on one hand, there is a control and inhibition of the
inﬂammatory process and consequently of the inﬂammatory inﬁl-
trate. On the other hand, there is a control on the arterial remodel-
ing. NF-jB inhibition determines a suppression of the expression of
cell proliferation genes. The modulation of inducible nitric oxide
synthase (iNOS) controls the action of cGMP, giving vasodilation
and anti-proliferation. The modulation of COX2, 5-LOX and PLA2
explicates a control on the arachidonic acid pathway and conse-
quently on prostacyclin which gives vasodilation and anti-prolifer-
ation as well. Curcumin is a low cost therapeutic solution, well
tolerated. The existing trials did not show side effects, except for
diarrhea. Even though there are no long term studies on humans.
Its main limits are poor bioavailability, rapid metabolism, low gas-
trointestinal absorption, rapid systemic elimination and low solu-
bility in water. The new formulation of curcumin, complexed
with hydroxypropyl ether derivatives of cyclodextrin is stable,
highly water-soluble, bioavailable, and easily produced. So it seems
to bridge the limits, permitting an administration by either the
intravenous or inhalation routes.
Possible clinical investigation
So far it is known oral curcumin pharmacokinetics. A ﬁrst step is
to evaluate oral curcumin speciﬁc pharmacodynamics for IPAH. It
is possible to do it confronting curcumin with a placebo. So, if oral
curcumin shows good efﬁcacy it should be tested in comparison
with the standard therapy. In a second step it is possible to proceed
from two results that we could obtain from the previous step. If
oral curcumin does not show a major efﬁcacy on the standard ther-
apy, other types of formulation could be tested in comparison with
it. These formulations could be then administered intravenously or
via inhalation. Otherwise, if oral curcumin shows a major efﬁcacy,
pharmacokinetics should be increased and it is necessary to ame-
liorate patient compliance to therapy. In both cases new curcumin
formulations are required possibly starting from CDC which has
been already developed. Either the intravenous or the inhalatory
formulation has to be studied in pharmacokinetics. Subsequently
they have to be studied in their pharmacodynamics toward IPAH,
ﬁrstly in comparison with a placebo. If good efﬁcacy is achieved,
they have to be tested secondly in comparison with the standard
therapy.
Conclusions
Curcumin has been used for thousands of years in Ayurvedic
medicine to treat various diseases. In the last decades it has been
926 E. Bronte et al. /Medical Hypotheses 81 (2013) 923–926studied its mechanisms of activity and its pharmacological proper-
ties. It has been considered a potent anti-inﬂammatory agent use-
ful for inﬂammatory diseases. Along the years its poor
bioavailability and rapid metabolism have limited its therapeutic
use. For this reason some studies have developed new formula-
tions of curcumin complexed with other molecules. Curcumin af-
fects numerous molecular targets and pathways, so in our
opinion it could be used as therapeutic agent in IPAH. Clearly some
studies are required to evaluate its efﬁcacy on this disease. We pro-
pose herein an idea of how a clinical trial could be designed.
Conﬂict of interest
Nothing to disclose.
References
[1] McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus
document on pulmonary hypertension: a report of the American College of
cardiology foundation task force on expert consensus documents and the
American Heart Association: developed in collaboration with the American
College of Chest Physicians, American Thoracic Society, Inc., and the
Pulmonary Hypertension Association. Circulation 2009;119(16):2250–94.
[2] Price LC, Wort SJ, Perros F, et al. Inﬂammation in pulmonary arterial
hypertension. Chest 2012;141(1):210–21.
[3] Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of
disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8(8):443–55.
[4] Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J
Clin Invest 2008;118(7):2372–9.
[5] McLaughlin VV, Davis M, Cornwell W. Pulmonary arterial hypertension. Curr
Probl Cardiol 2011;36(12):461–517.
[6] Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classiﬁcation of
pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl. 1):S43–54.
[7] Ulrich S, Fischler M, Speich R. Update on therapies for pulmonary
hypertension. Swiss Med Wkly 2007;137(5–6):73–82.
[8] Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin
Res Cardiol 2007;96(8):527–41.
[9] Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets
2011;12(3):332–47.
[10] Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the
evidence from in vitro, animal and human studies. Br J Nutr
2010;103(11):1545–57.[11] Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits
constitutive and IL-6-inducible STAT3 phosphorylation in human multiple
myeloma cells. J Immunol 2003;171(7):3863–71.
[12] Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties
in laboratory studies and clinical trials. Antioxid Redox Signal
2008;10(3):511–45.
[13] Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune
system. Annu Rev Immunol 1994;12:141–79.
[14] Tak PP, Firestein GS. NF-kappaB: a key role in inﬂammatory diseases. J Clin
Invest 2001;107(1):7–11.
[15] Munford RS, Pugin J. Normal responses to injury prevent systemic
inﬂammation and can be immunosuppressive. Am J Respir Crit Care Med
2001;163(2):316–21.
[16] Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inﬂammatory cytokine
production by human peripheral blood monocytes and alveolar macrophages.
Pharmacol Res 1999;39(1):41–7.
[17] Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcumin), a
non-steroidal anti-inﬂammatory agent. J Pharm Pharmacol
1973;25(6):447–52.
[18] Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (diferuloylmethane)
inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to
endothelial cells by suppression of cell surface expression of adhesion
molecules and of nuclear factor-kappaB activation. Biochem Pharmacol
1998;55(6):775–83.
[19] Lao CD, Rufﬁn 4th MT, Normolle D, et al. Dose escalation of a curcuminoid
formulation. BMC Complement Altern Med 2006;17(6):10.
[20] Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a
chemopreventive agent, in patients with high-risk or pre-malignant lesions.
Anticancer Res 2001;21(4B):2895–900.
[21] Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the
anti-inﬂammatory agent, against neurodegenerative, cardiovascular,
pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem
Cell Biol 2009;41(1):40–59.
[22] Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Inﬂuence of
piperine on the pharmacokinetics of curcumin in animals and human
volunteers. Planta Med 1998;64(4):353–6.
[23] Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer
2005;41(13):1955–68.
[24] Vareed SK, Kakarala M, Rufﬁn MT, et al. Pharmacokinetics of curcumin
conjugate metabolites in healthy human subjects. Cancer Epidemiol
Biomarkers Prev 2008;17(6):1411–7.
[25] Suresh MV, Wagner MC, Rosania GR, et al. Pulmonary administration of a
water-soluble curcumin complex reduces severity of acute lung injury. Am J
Respir Cell Mol Biol 2012;47(3):280–7.
[26] Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin:
biomarkers of systemic activity and compliance. Clin Cancer Res
2004;10(20):6847–54.
